New Clinical Data Show Enoxaparin Significantly Reduces the Risk of Repeat Heart Attacks and Stroke in Patients Undergoi

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expect," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although Sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include risks that may arise from the Department of Justice's criminal investigation on the Plavix(R) proposed settlement with Apotex, the adverse impact of generic product distributed into the market prior to the Court's injunction, the outcome of sanofi-aventis' patent infringement litigation against Apotex and other entities, the potential launch of a generic clopidogrel bisulfate product by other entities, as well as those risks and uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2005. Other than as required by applicable law, Sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Contact: Salah Mahyaoui, +33-6-73-68-78-88, salah.mahyaoui@sanofi-aventis.com